AN ACT relating to coverage for rapid whole genome sequencing.
Summary
HB401 would require fully insured and self-insured health benefit plans offered to Kentucky public employees to cover and reimburse rapid whole genome sequencing in specified pediatric cases. The bill defines rapid whole genome sequencing as a test of the entire human genome, including coding and non-coding regions and mitochondrial DNA, with preliminary results in seven days and final results in fifteen days. Coverage would apply when the patient is under 21, has a complex acute illness of unknown cause, and is being treated in an intensive care unit or other high-acuity hospital setting.
The bill also sets medical-necessity criteria for when the test must be covered, including situations where a broad differential diagnosis would otherwise require multiple genetic tests, where a treating provider determines that a timely molecular diagnosis is needed to guide care, and where the patient presents with certain serious findings such as congenital anomalies, refractory seizures, abnormal cardiac or metabolic findings, or a relevant family history. In addition, the bill addresses the handling of genetic data by treating it as protected health information under HIPAA and HITECH, while allowing use in scientific research only with express informed consent and permitting consent to be revoked, after which the data must be expunged from repositories.
Impact
HB401 would add a new coverage mandate to KRS Chapter 18A for public employee health plans, requiring reimbursement for rapid whole genome sequencing when the statutory conditions are met. It would affect state employee health benefits, insurers administering those plans, healthcare providers ordering genetic testing, and laboratories performing the sequencing. The bill also creates rules governing the privacy, secondary use, and deletion of genetic data generated through covered testing, reinforcing federal health privacy protections and adding state-level consent and revocation requirements.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the bill appears to be framed as a targeted healthcare access measure for critically ill children and families facing diagnostic uncertainty. Its structure suggests a policy goal of improving timely diagnosis and treatment in high-acuity pediatric cases while also addressing privacy concerns around genetic information. No opposing or supporting statements are available in the record provided, so the overall sentiment cannot be measured from discussion or voting history.
Contention
The main potential points of contention are likely the cost and scope of the insurance mandate, the medical-necessity thresholds that determine eligibility, and the handling of sensitive genetic data. Insurers and plan administrators may be concerned about utilization, reimbursement, and administrative burden, while providers and patient advocates may support the bill as a way to speed diagnosis in severe pediatric cases. Privacy and research-use provisions could also draw attention, especially the requirement for express consent and the mandate to expunge data after revocation.